Kidney Week

Abstract: TH-PO653

Low Circulating CD34+ Cell Count Is a Significant Predictor of Cardiovascular Death Among Chronic Hemodialysis Patients

Session Information

• Development, Stem Cells, Regenerative Medicine - I
  October 25, 2018 | Location: Exhibit Hall, San Diego Convention Center
  Abstract Time: 10:00 AM - 12:00 PM

Category: Development, Stem Cells, and Regenerative Medicine

• 502 Development, Stem Cells, and Regenerative Medicine: Clinical

Authors

• Kaihan, Ahmad Baseer, Nagoya University Graduate School of Medicine, Nagoya city, Aichi-Ken, Japan

Ahmad Baseer Kaihan,

• Yasuda, Yoshinari, Nagoya University Graduate School of Medicine, Nagoya, Aichi-ken, Japan, Nagoya, Japan

Yoshinari Yasuda,

• Imaizumi, Takahiro, Nagoya University Graduate School of Medicine, Nagoya, Japan

Takahiro Imaizumi,

• Okazaki, Masaki, Nagoya University Graduate School of Medicine, Nagoya, Japan

Masaki Okazaki,

• Tsuboi, Naotake, Nagoya University Graduate School of Medicine, Nagoya, Japan

Naotake Tsuboi,

• Maruyama, Shoichi, Nagoya University Graduate School of Medicine, Nagoya, Japan

Shoichi Maruyama,

Background

Circulating CD34-positive (CD34+) cells play an essential role in neo-angiogenesis and in maintaining vascular endothelial function. A reduced CD34+ cell count was reported that associated with cardiovascular events and all-cause mortality. In this study, we aimed to validate association of low CD34+ cell count with cardiovascular death and all-cause mortality among chronic hemodialysis patients with longer follow up period.

Methods

In this prospective cohort study, 216 CKD patients on chronic hemodialysis enrolled from Mar 2005 to May 2005 and followed by the end of 2017 at Nagoya Kyoritsu Hospital. A cutoff number (0.41 cells/µl) for circulating CD34+ cells was determined by dividing all patients into two equal group of low CD34+ CPCs group (n=108) vs high CD34+ CPCs group (n=108) to predict cardiovascular death in the future, and the number of circulating CD34+ cells determined by flow cytometry at the time of enrollment. The primary outcome was cardiovascular death and all-cause mortality.

Results

During an average 59 months of follow-up, of 139 (64.7%) deaths, 38 (17.7%) cardiovascular deaths occurred. Cumulative cardiovascular death-free survival was significantly less in the low numbers of circulating CD34+ cells group. By multivariate analyses, age, DM, current smoking, history of CVD, and GNRI were significantly associated with all-cause mortalities, whereas, low numbers of circulating CD34+ cells (HR;1.98, p=0.037), GNRI (HR;0.95,p=0.042), and history of CVD (HR;2.92; p=0.031) were significant predictors for cardiovascular deaths.

Conclusion

This study revealed that a low number of circulating CD34⁺ cells is significantly associated with risk of cardiovascular deaths, but not with all-cause mortalities in patients on chronic hemodialysis.

Funding

• Commercial Support